Development of Oncolytic Vectors Based on Human Adenovirus Type 6 for Cancer Treatment

Human Adenovirus type 6 (HAdV-C6) is a promising candidate for the development of oncolytic vectors as it has low seroprevalence and the intrinsic ability to evade tissue macrophages. However, its further development as a therapeutic agent is hampered by the lack of convenient cloning methods. We ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Osipov, Ivan D., Vasikhovskaia, Valeriia A., Zabelina, Daria S., Kutseikin, Sergei S., Grazhdantseva, Antonina A., Kochneva, Galina V., Davydova, Julia, Netesov, Sergey V., Romanenko, Margarita V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865941/
https://www.ncbi.nlm.nih.gov/pubmed/36680222
http://dx.doi.org/10.3390/v15010182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865941/
https://www.ncbi.nlm.nih.gov/pubmed/36680222
http://dx.doi.org/10.3390/v15010182

Ejemplares similares